In the near future, who are the top five pharmaceutical companies applying for the number of generic drugs?

[industry trends of pharmaceutical network] at present, with the continuous implementation of bidding and procurement policies in various regions, pharmaceutical companies are no longer in the "wait-and-see" state, and more and more pharmaceutical companies are increasing their R & D investment in the conformity evaluation of generic drugs The industry said that the generic drug market war is imminent, with more varieties of pharmaceutical companies will stand out According to data statistics, 375 varieties have been applied for conformity assessment and review of generic drugs, 1275 applications have been accepted, of which 603 are under review According to the distribution of drug application areas, the number of application for digestive system and metabolic drugs, cardiovascular system drugs and systemic anti infective drugs is mostly In addition, according to the number of applications, the R & D strength of pharmaceutical enterprises with more applications is often stronger Among them, Qilu pharmaceutical has applied for 67 applications, while Kelun pharmaceutical, Yangzi River, China Bio pharmaceutical and Shanghai Pharmaceutical have all applied for more than 40 applications Qilu pharmaceutical: the number of applications is 67 Qilu pharmaceutical has applied for 67 generic drug conformity evaluation varieties, which is an enterprise with a large number of applications nationwide Since the end of 2018, the company has actively responded to the call of the state, continuously improved the quality of drugs, actively reduced the price of drugs, and reduced the burden of drug use for patients Among them, the price of gefitinib tablets of Qilu pharmaceutical was adjusted to 547 yuan / box after the consistency evaluation, which was nearly 90% lower than that of the original research drug Kelun pharmaceutical: the number of applications is 57 After Qilu pharmaceutical, the number of applications is 57 On December 27, 2018, Kelun pharmaceutical announced that its tinidazole tablet became the first drug in China to pass the consistency evaluation of generic drugs and obtain the drug registration approval, which is mainly used to treat diseases such as abdominal infection, pelvic infection and intestinal amebiasis caused by anaerobic bacteria In March of this year, Kelun pharmaceutical also announced that two hundred million grades of "fluconazole tablets" and "acyclovir tablets" passed the consistency evaluation of generic drugs Yangzi River: the number of applications is 48 Since 2014, Yangzi River Pharmaceutical industry has made great efforts to promote the consistency evaluation of generic drugs, and started the re evaluation of several chemical generic drugs At present, the Yangtze River Pharmaceutical industry has declared 48 According to statistics, as of March 22 this year, eight products in Yangzi River have passed the conformity evaluation of generic drugs, six of which have passed the evaluation, and more than 20 varieties have been declared and are in the state of review China Biopharmaceutics: 45 applications Currently, China Biopharmaceutics has a total of 45 applications In March this year, Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., a subsidiary of the company, sent good news about the consistency evaluation of "olmesartan ester tablet" and "entecavir capsule", among which olmesartan ester tablet is the domestic product whose price has passed the consistency evaluation Shanghai medicine: the number of 43 Shanghai medicine applications indicated that in 2018, the company completed the consistency evaluation and application of 27 varieties and 32 product specifications of solid preparations At present, the number of applications has reached 43 As of January 11, Shanghai Pharmaceutical Co., Ltd has set up a project to carry out the consistency evaluation of 10 varieties and 20 specifications of injections, of which 2 varieties have been declared and 8 varieties are under orderly promotion According to the analysis of the industry, the consistency evaluation of SHP has two characteristics First, the number of varieties is large, and the overall progress is fast; second, the products for consistency evaluation include not only large varieties, but also some cold products, such as primachloroquine phosphate tablets, bromepyridine tablets, etc.